How Lin BioScience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TPEX:6696 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
0
-1,363
1,244
1,613
30 Sep 25
0
-1,193
962
1,458
30 Jun 25
0
-1,024
679
1,304
31 Mar 25
0
-884
518
1,203
31 Dec 24
0
-744
357
1,101
30 Sep 24
0
-738
307
1,060
30 Jun 24
0
-732
258
1,018
31 Mar 24
0
-709
251
936
31 Dec 23
0
-687
243
854
30 Sep 23
0
-603
213
728
30 Jun 23
0
-518
183
601
31 Mar 23
0
-416
153
461
31 Dec 22
0
-314
124
321
30 Sep 22
0
-252
109
269
30 Jun 22
0
-190
94
217
31 Mar 22
0
-380
97
235
31 Dec 21
0
-435
94
245
30 Sep 21
0
-415
78
222
30 Jun 21
0
-394
62
200
31 Mar 21
0
-186
53
156
31 Dec 20
0
-152
52
145
30 Sep 20
0
-197
47
161
30 Jun 20
0
-243
42
178
31 Mar 20
0
-259
45
199
31 Dec 19
0
-235
45
193
30 Sep 19
0
-209
48
167
30 Jun 19
0
-183
51
141
31 Mar 19
0
-161
51
123
31 Dec 18
0
-139
52
104
30 Sep 18
0
-134
49
100
30 Jun 18
0
-128
46
97
31 Mar 18
0
-144
42
110
31 Dec 17
0
-159
38
123
31 Dec 16
0
-63
14
49
Quality Earnings: 6696 is currently unprofitable.
Growing Profit Margin: 6696 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6696 is unprofitable, and losses have increased over the past 5 years at a rate of 33.3% per year.
Accelerating Growth: Unable to compare 6696's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6696 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (25.2%).
Return on Equity
High ROE: 6696 has a negative Return on Equity (-10.27%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/08/17 07:36
End of Day Share Price
2026/08/14 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lin BioScience, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.